Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Peter C. Yang"'
Autor:
Samuel M. Rubinstein, Tarsheen K. Sethi, Peter C. Yang, Bishal Gyawali, Neeta K. Venepalli, Candice Schwartz, Donna R. Rivera, Jeremy L. Warner
Publikováno v:
JCO Clin Cancer Inform
Cancer medicine has grown increasingly complex in recent years with the advent of precision oncology and wide utilization of multidrug regimens. Representing this increasingly granular knowledge is a significant challenge. As users and managers of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::648093345d2e6eaf7e736ca2e3f6f472
https://pubmed.ncbi.nlm.nih.gov/33411619
https://pubmed.ncbi.nlm.nih.gov/33411619
Publikováno v:
JCO Clinical Cancer Informatics
PURPOSE Due to decades of nonstandardized approaches to the naming of chemotherapy regimens, representation in electronic health records and secondary systems is highly variable. This hampers efforts to understand patterns of chemotherapy usage at th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4904ac26e0d71078125cde7ffd376123
https://pubmed.ncbi.nlm.nih.gov/31990580
https://pubmed.ncbi.nlm.nih.gov/31990580
Autor:
Candice Schwartz, Qingxia Chen, Jess Behrens, Seema Nagpal, Shervin A. Etemad, Benjamin F. Tillman, Ronald S. Go, Kristin Wuichet, Elizabeth Sigworth, Xuanyi Li, John P. Greer, Travis J. Osterman, Ivy Abraham, Summer B. Dewdney, Andrew J. Cowan, Andrew Malty, Samuel M. Rubinstein, Neeta K. Venepalli, Jeremy L. Warner, Adrianne H. Wu, Peter C. Yang, Sanjai Sharma, Hermina D Fernandes, Eddy J. Chen, Matthew J. Rioth, Elizabeth I. Buchbinder, Rozina A. Chowdhery, Ari Seifter, Edward P. Ambinder, Martin W. Schoen, Sanjay R. Mohan, Naina Singh, Michael K. Gibson
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
BackgroundClinical trials establish the standard of care for cancer and other diseases. While social network analysis has been applied to basic sciences, the social component of clinical trial research is not well characterized. We examined the socia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2ccdf721284ca5c95d6c73578731e11
https://pubmed.ncbi.nlm.nih.gov/33067482
https://pubmed.ncbi.nlm.nih.gov/33067482
Publikováno v:
JCO Clinical Cancer Informatics
Purpose Despite the plethora of randomized controlled trial (RCT) data, most cancer treatment recommendations are formulated by experts. Alternatively, network meta-analysis (NMA) is one method of analyzing multiple indirect treatment comparisons. Ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ed8a24555827ffb51d54bfe238c7d21
https://doi.org/10.1200/cci.17.00079
https://doi.org/10.1200/cci.17.00079
Autor:
Samuel M. Rubinstein, Ali Raza Khaki, Bishal Gyawali, Peter C. Yang, Jeremy L. Warner, Martin W. Schoen
Publikováno v:
Journal of Clinical Oncology. 38:2072-2072
2072 Background: Treatment successes in cancer are achieved through new drugs tested in clinical trials. However, drug discovery has been disparate across cancer types for various reasons. We sought to investigate if the number of trials used to supp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4a6bf8d5b321fbb671775204a55d915
https://doi.org/10.1200/jco.2020.38.15_suppl.2072
https://doi.org/10.1200/jco.2020.38.15_suppl.2072
Publikováno v:
JCO clinical cancer informatics. 2
Purpose The systemic treatment of cancer is primarily through the administration of complex chemotherapy protocols. To date, this knowledge has not been systematized, because of the lack of a consistent nomenclature and the variation in which regimen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2d872194eeb06bf65ef02b64d4e6a0d
https://pubmed.ncbi.nlm.nih.gov/30238070
https://pubmed.ncbi.nlm.nih.gov/30238070
Publikováno v:
Journal of Oncology Practice. 11:e336-e350
Cancer care involves extensive knowledge about numerous chemotherapy drugs and chemotherapy regimens. This information is constantly evolving, and there has been no freely available, comprehensive, centralized repository of chemotherapy information t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbfaed455fa868716fd0fba95d085b8d
https://doi.org/10.1200/jop.2014.001511
https://doi.org/10.1200/jop.2014.001511
Autor:
Christian G. Reich, Michael J. Gurley, Andrew E. Williams, Zachary H. Moldwin, Rimma Belenkaya, Dmitry Dymshyts, Harry Hochheiser, Jeremy L. Warner, Peter C. Yang
Publikováno v:
J Biomed Inform
Systematic application of observational data to the understanding of impacts of cancer treatments requires detailed information models allowing meaningful comparisons between treatment regimens. Unfortunately, details of systemic therapies are scarce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffc79cddcc55a7dd1abc20af6d9c9f23
https://doi.org/10.1016/j.jbi.2019.103239
https://doi.org/10.1016/j.jbi.2019.103239
Autor:
Charles Ginther, Ronald W. Busuttil, Alexey Aleshin, Amrita J. Desai, Peter C. Yang, Judy Dering, Danyun Zhao, Richard S. Finn, Erika von Euw, Dennis J. Slamon
Publikováno v:
Hepatology. 57:1838-1846
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and is the third leading cause of cancer death worldwide. Recently, the multitargeted kinase inhibitor sorafenib was shown to be the first systemic agent to improve survival in advanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ef1428be7ab227413dd7bd8eca3c3c4
https://doi.org/10.1002/hep.26223
https://doi.org/10.1002/hep.26223
Autor:
Matthew J. Budoff, Radhakrishna R. Kallem, Ruth F. Dubin, Peter C. Yang, Jackson T. Wright, Jason Roy, Rajat Deo, Raymond R. Townsend, Martin G. Keane, Jiang He, Daohang Sha, Thomas P. Cappola, Amanda H. Anderson, Nisha Bansal, Shaista Malik, Mahboob Rahman, Michael G. Shlipak, Anna Porter, Alan S. Go
Background and objectives Heart failure is the most frequent cardiac complication of CKD. Left ventricular hypertrophy is common and develops early in CKD, but studies have not adequately evaluated the association of left ventricular mass index with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a97547428b76a88bfe874f6b14ddeb3
https://europepmc.org/articles/PMC5220650/
https://europepmc.org/articles/PMC5220650/
